These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8899222)

  • 21. Zoledronate in the treatment of osteolytic bone metastases.
    Lipton A
    Br J Clin Pract Suppl; 1996 Sep; 87():21; discussion 22. PubMed ID: 8995015
    [No Abstract]   [Full Text] [Related]  

  • 22. [Bone changes in multiple myeloma--current etiopathogenic, diagnostic and therapeutic aspects].
    Sakalová A; Mistrík M; Gazová S; Chabronová I; Hrubisko M; Skultétyová D; Mociková H
    Vnitr Lek; 2002 Jul; 48(7):642-8. PubMed ID: 12197408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonates in cancer therapy.
    Green JR
    Curr Opin Oncol; 2002 Nov; 14(6):609-15. PubMed ID: 12409650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Mechanism and treatment of cancer metastasis to bone].
    Yoneda T
    Clin Calcium; 2005 Jul; 15(7):29-37. PubMed ID: 15995293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The future of bisphosphonates in cancer.
    Coleman RE; Purohit OP; Vinholes JJ
    Acta Oncol; 1996; 35 Suppl 5():23-9. PubMed ID: 9142961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
    Body JJ
    Cancer; 2003 Feb; 97(3 Suppl):859-65. PubMed ID: 12548587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pamidronate in the treatment of osteolytic bone metastases in breast cancer patients.
    Theriault R
    Br J Clin Pract Suppl; 1996 Sep; 87():8-12; discussion 13-4. PubMed ID: 8995011
    [No Abstract]   [Full Text] [Related]  

  • 30. Pamidronate in the treatment of bone metastases--the European experience.
    Ford JF
    Br J Clin Pract Suppl; 1996 Sep; 87():3-4; discussion 13-4. PubMed ID: 8995009
    [No Abstract]   [Full Text] [Related]  

  • 31. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.
    Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Fontana D; Angeli A
    J Urol; 2001 Dec; 166(6):2023-31. PubMed ID: 11696699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
    Rosen LS
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):28-32. PubMed ID: 12584692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical value of bisphosphonates in cancer therapy.
    Lüftner D; Henschke P; Possinger K
    Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommendations for zoledronic acid treatment of patients with bone metastases.
    Berenson JR
    Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bisphosphonates and bone metastases of solid tumors: therapeutic interest despite its anti-resorptive properties].
    Clézardin P
    Prog Urol; 2003 Apr; 13(2 Suppl 1):28-35. PubMed ID: 12815807
    [No Abstract]   [Full Text] [Related]  

  • 37. Managing cancer-related skeletal events with bisphosphonates.
    Rule S
    Hosp Med; 2004 Jun; 65(6):355-60. PubMed ID: 15222212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Myelomatous bone. Histomorphometric study and therapeutic effects].
    Charhon SA; Valentin-Opran A; Edouard C; Delmas PD; Meunier PJ
    Rev Rhum Mal Osteoartic; 1984 Dec; 51(11):657-62. PubMed ID: 6523017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Possibilities of diphosphonates in the therapy of bone diseases].
    Bonjour JP; Rizzoli R
    Rev Med Suisse Romande; 1990 Aug; 110(8):691-4. PubMed ID: 1699260
    [No Abstract]   [Full Text] [Related]  

  • 40. Investigating the efficacy of bisphosphonates treatment against multiple myeloma induced bone disease using a computational model.
    Ji B; Yang Q; Genever PG; Fagan MJ
    Biomed Mater Eng; 2014; 24(6):3373-8. PubMed ID: 25227047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.